{"id":"b7834254-dbe0-5dcf-8c39-9ea5ef3c058a","stable_key":"18100170-a014-51c3-adeb-9dab4162b8cc:airway-il10-null","predicate":"context_dependent_observation","statement":"BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"6050f501-2a4f-5d65-bf7b-8fa649ef30d3","mechanism_event_label":"BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.","subject":{"id":"657e1f4c-401e-5584-99d9-bb685bbd2bc7","slug":"thymulin-expression-plasmid","display_name":"Engineered thymulin-expression plasmid delivery","entity_type_key":"chemical_species"},"object":{"id":"4f0806a8-80a5-5921-a804-7866f51bc169","slug":"mouse-il10","display_name":"Mouse interleukin-10 / Il10","entity_type_key":"cytokine"},"evidence_count":1,"mechanism_event":{"id":"6050f501-2a4f-5d65-bf7b-8fa649ef30d3","stable_key":"18100170-a014-51c3-adeb-9dab4162b8cc:airway-il10-null-event","event_type":"experimental_observation","label":"BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.","description":"A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"657e1f4c-401e-5584-99d9-bb685bbd2bc7","slug":"thymulin-expression-plasmid","display_name":"Engineered thymulin-expression plasmid delivery","entity_type_key":"chemical_species"},"role":"tested factor","stoichiometry":null,"state_label":"Thymulin-expression plasmid nanoparticles","sequence_order":0,"notes":""},{"entity":{"id":"4f0806a8-80a5-5921-a804-7866f51bc169","slug":"mouse-il10","display_name":"Mouse interleukin-10 / Il10","entity_type_key":"cytokine"},"role":"measured outcome","stoichiometry":null,"state_label":"mixed","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Thymulin-expression plasmid nanoparticles\", \"comparator\": \"Allergic disease control\", \"endpoint\": \"BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.\", \"effect_direction\": \"mixed\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse allergic airway model; BAL protein and isolated-lymphocyte transcript are distinct readouts.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b1d7b630-ac87-59a1-ad52-47c07e577e88","evidence_kind":"source_excerpt","locator":"Lines 84-84","start_line":84,"end_line":84,"excerpt":"A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)","model_system":"Mouse allergic airway model; BAL protein and isolated-lymphocyte transcript are distinct readouts.","directness":"reported_statement","verification_status":"source_recorded","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e1871d49-9c6b-547b-a1bb-6e2b9270ca89","stable_key":"import-18100170-a014-51c3-adeb-9dab4162b8cc","title":"Thymulin: detailed mechanisms of action (reviewed 3 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"6e8ed0d7a5e23fc822f2ab418e0c4fb2411c01fcaa330039e8d7d93218cacc88","revision_id":"8c0e3449-9bbd-57c0-bb5e-de83f044f2ac","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}